prTMS as an Intervention for Bradykinesia in Parkinson's Disease
This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.
Study identifier: NCT07397377. Status: RECRUITING. Phase: NA.
Eligibility
Criteria: Inclusion Criteria: Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society. Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent. Exclusion Criteria: Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin). Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis. History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS). Close relatives suffering from epilepsy/conditions associated with increased risk of seizures. Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial. Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
- Minimum age: 18 Years
- Maximum age: 80 Years
Participating locations
- DRCMR, Hvidovre
Study records are sourced from ClinicalTrials.gov. Confirm current eligibility, recruiting status, and locations in the official record.